Breast Cancer Pathways: Adjuvant

Patient Name:_____ Date of Birth:_____

Member Number: _____ Treatment Start Date:_____

Pathology:_____ **Stage**:_____

Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op **ECOG Performance Status**:_____ ICD-10 Code:_____

Biomarkers/Characteristics: (Select all that apply)

Estrogen Receptor (ER): __Negative __Positive

Progesterone Receptor (PR): __Negative __Positive

HER2 status by FISH/CISH: __Negative __Positive __Equivocal

or by IHC: __0 __1+ __2+ __3+

OncotypeDx: __Low* __Intermediate __High __Not Done/Reported

Include ovarian suppression (pre-menopause only): __Yes __No __Unknown

Adjuvant Therapy | HER2 Negative*

___**ddAC → weekly T**: dose dense doxorubicin (Adriamycin) and cyclophosphamide followed by weekly paclitaxel

___**TC**: docetaxel (Taxotere) and cyclophosphamide

Adjuvant Therapy | HER2 Positive

___**AC → TH**: doxorubicin (Adriamycin) and cyclophosphamide followed by paclitaxel and trastuzumab (Herceptin)†

___**TCH**: docetaxel (Taxotere), carboplatin, and trastuzumab (Herceptin)†

___**TH**: paclitaxel and trastuzumab (Herceptin)† **(Pathway for stage I, HER2 positive breast cancer only)**

Adjuvant Therapy | HER2 Negative | Hormone Receptor (ER/PR) Negative | Residual Disease following Neoadjuvant Therapy

___Capecitabine (Xeloda)

Adjuvant Therapy | HER2 Positive | Residual Disease following Neoadjuvant Therapy

___Trastuzumab emtansine (Kadcyla)

*Adjuvant chemotherapy pathways do NOT apply to individuals with hormone-receptor positive, lymph node negative, OncotypeDX™ LOW risk score

†Administration of trastuzumab (Herceptin) is limited to 17 cycles (approximately 1 year)

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 2/19/2019 | Effective date: 5/13/2019